ArticleCase reports in hematology2026
Rare Case of ALK-Positive Large B-Cell Lymphoma in a Young Adult: Diagnostic and Therapeutic Challenges.
Article in Case reports in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rare Case of ALK-Positive Large B-Cell Lymphoma in a Young Adult: Diagnostic and Therapeutic Challenges.Case reports in hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a rare case of ALK-positive large B-cell lymphoma (ALK + LBCL) in a previously healthy 20-year-old male, who presented with two weeks of worsening diffuse abdominal pain and weight loss, and was subsequently found to have extensive mesenteric and retroperitoneal lymphadenopathy. Biopsies confirmed the diagnosis of Stage II bulky ALK + LBCL, supported by characteristic immunohistochemical findings including granular cytoplasmic ALK staining and the absence of CD20 expression. Due to the rarity of this aggressive disease, treatment options remain uncertain, and a multidisciplinary consensus for management was required. The patient was treated with dose-adjusted EPOCH chemotherapy, with rituximab added in subsequent cycles despite predominant CD20 negativity. Interim PET/CT scans demonstrated a favorable metabolic response, spotlighting the diagnostic and therapeutic challenges in managing this rare and poorly understood lymphoma subtype.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.